In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four ...

In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or ...

Johnson & Johnson (JNJ) stock in focus as Darzalex SC developed with Halozyme (HALO) and Genmab (GMAB) receives EU nod for ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

Over the past three decades, tremendous achievements have been made in the treatment of patients with multiple myeloma (MM), ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit ...

Multiple myeloma (MM) remains a complex and heterogeneous hematologic malignancy with evolving therapeutic challenges. In recent years, immunotherapy has ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Glenmark's arm IGI Therapeutics signs a $700 million licensing deal with AbbVie for its cancer drug ISB 2001, with potential ...